• Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clinical programs in Poland.
• Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients.
• Clinical programs planned to be included in the agreement span multiple solid tumor types, including lung, breast, and colorectal cancers.

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, is entering a strategic agreement with BioNTech to benefit Polish cancer patients by supporting trial site activation and patient recruitment for multiple investigational immunotherapies of BioNTech’s oncology pipeline in Poland.

The parties plan to leverage Ryvu’s operational excellence, expertise in oncology clinical operations, and existing trial site network to streamline access of Polish patients to BioNTech’s investigational immunotherapies. BioNTech intends to design and roll out clinical trials for some of the company’s priority programs in Poland and fund Ryvu’s services under the agreement. The clinical programs planned to be included in the agreement span multiple solid tumor types, including lung, breast, and colorectal cancer.

Kamil Sitarz, Chief Operating Officer, Management Board Member of Ryvu Therapeutics, said: "We are thrilled to build on our strong research relationship with BioNTech by entering a strategic agreement that leverages Ryvu’s operational excellence and expertise in oncology clinical operations to bring more BioNTech clinical programs to Poland. BioNTech’s science and innovation, combined with our shared ambition to bring innovative treatments to patients quickly, create a powerful momentum. We look forward to working together to streamline clinical trial activation and patient recruitment for BioNTech’s cancer immunotherapy clinical trials in Poland."